MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
October 05 2021 - 10:00AM
Business Wire
MyMD to launch two simultaneous Phase 2 trials
during the current quarter to study MYMD-1’s function in extending
healthy lifespan and treating COVID-19-associated
depression
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan, today announced that it will present at
the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on
Thursday, October 7, 2021. The Company’s presentation will be
available for viewing that day at 10:10 a.m. ET on Benzinga’s live
stream channel.
During the presentation, MyMD President, Director and Chief
Medical Officer Chris Chapman, M.D. and Chief Scientific Officer
Adam Kaplin, M.D., Ph.D. will discuss the Company’s product
pipeline with diversified indications for MYMD-1 as an
immunometabolic regulator and Supera-CBD as a synthetic CBD
derivative.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
rather than only addressing the symptoms. MYMD-1 is a drug platform
based on a clinical stage small molecule that regulates the immune
system to control TNF-α, which drives chronic inflammation, and
other pro-inflammatory cell signaling cytokines. MYMD-1 is being
developed to delay aging, increase longevity, and treat autoimmune
diseases and COVID-19- associated depression. The Company’s second
drug platform, Supera-CBD, is being developed to treat chronic
pain, addiction and epilepsy. Supera-CBD is a novel synthetic
derivative of cannabidiol (CBD) and is being developed to address
and improve upon the rapidly growing CBD market, which includes
both FDA approved drugs and CBD products not currently regulated as
drugs. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021, filed by MyMD on August 16,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211005005113/en/
Investor: Robert Schatz (646) 421-9523 rschatz@mymd.com
www.mymd.com
Media: media@mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024